How Hims & Hers Makes its Money: Revenue Breakdown

Key Takeaways

• Hims & Hers generated $1.97 billion in FY2024 revenue — up +65.3% year-over-year — driven by GLP-1 weight loss, hair loss, and ED subscription growth
• The business is 97% online subscription revenue ($1.91B); wholesale retail is a small, fast-growing complement ($63M, +271%)
• Gross margin: 66.1% ($1.30B gross profit) — exceptional for a company shipping physical pharmaceutical products; reflects the DTC model and in-house compounding pharmacy
• Turned decisively profitable in FY2024: operating income $168M (8.5% margin), net income $126M — vs. near-breakeven in FY2023
• GLP-1/semaglutide is the biggest growth driver and the biggest regulatory risk: compounded semaglutide brought a wave of new weight loss subscribers; the FDA’s shortage resolution in Feb 2025 is forcing a pivot
• The subscription model for chronic conditions (hair loss, ED, weight management) creates high lifetime value — patients who see results rarely stop treatment
• In-house compounding pharmacy enables lower-cost personalized formulations that branded drug makers cannot replicate
• Novo Nordisk (Ozempic/Wegovy) and Eli Lilly (Mounjaro/Zepbound) are both competitors (GLP-1 brands) and bellwethers — GLP-1 adoption growth benefits Hims’ addressable market while the shortage resolution threatens its supply model

How Does Hims & Hers Make its Money?

Hims & Hers Health, Inc. (ticker: HIMS) is a direct-to-consumer telehealth platform that connects patients with licensed healthcare providers through a digital-first experience — online consultation, prescription, and home delivery — for conditions that people commonly avoid discussing with a traditional doctor: hair loss, erectile dysfunction, skin concerns, mental health, and weight management.

Founded in 2017 by Andrew Dudum, the company launched as a men’s health brand under the Hims brand (primarily hair loss and ED), then expanded with the Hers brand targeting women’s health and skincare. The company went public via SPAC in January 2021. The 2023–2024 entry into GLP-1 weight loss medications catalyzed a step-change in growth: revenue jumped from $527M in FY2022 to $1.19B in FY2023 to $1.97B in FY2024.

The core business is a subscription model for chronic conditions. A customer pays a monthly fee for ongoing access to a provider relationship and medication delivery. Because hair loss, ED, and weight management are indefinite conditions with no cure, subscribers who see results tend to stay for years — creating high lifetime value from a single acquisition cost.

Hims & Hers (HIMS) Business Model

The DTC Telehealth Subscription Flywheel

Hims & Hers operates as a subscription business with a healthcare delivery layer. The customer journey:

1. Discovery: A user visits hims.com or hers.com, typically through paid digital advertising (Meta, Google), influencer marketing, or TV/podcast campaigns. Hims & Hers is one of the largest DTC healthcare advertisers in the U.S.

2. Online intake: The user completes a digital questionnaire about their health history, symptoms, and goals. This serves as the clinical intake form that a licensed provider reviews.

3. Provider consultation: A licensed healthcare provider (physician or nurse practitioner, employed or contracted by Hims & Hers’ affiliated medical groups) reviews the intake, may conduct an async video consultation, and issues a prescription if clinically appropriate.

4. Personalized formulation: Hims & Hers’ in-house compounding pharmacy (or an affiliated PCAB-accredited facility) compounds or dispenses the medication to the patient’s specific prescription.

5. Subscription delivery: Medication is shipped monthly. The patient is billed on a recurring subscription basis. As long as the patient renews and refills, revenue continues — with near-zero incremental customer acquisition cost.

6. Upsell and cross-sell: A hair loss subscriber is shown weight loss options; an ED subscriber may be offered mental health support. The single platform becomes the patient’s healthcare relationship.

Gross Margin Architecture: Why 66% for a Physical Product Business

Most pharmaceutical retailers operate at 20–30% gross margins. Hims & Hers achieves 66.1% because of three structural advantages:

1. Direct-to-consumer eliminates intermediaries. Traditional drug distribution flows: manufacturer → wholesaler → pharmacy → patient, with each link taking a cut. Hims & Hers goes manufacturer/compounder → patient directly, capturing the intermediary margin.

2. In-house compounding reduces drug costs. By operating its own compounding pharmacy, Hims & Hers can manufacture formulations at API (active pharmaceutical ingredient) cost plus compounding labor, rather than paying brand or even generic retail prices. A compounded semaglutide vial costs Hims & Hers far less to produce than the ~$1,300/month Wegovy list price.

3. Digital consultation is low-cost to deliver. An asynchronous online consultation costs a fraction of an in-person visit. Provider labor is the primary variable cost, but it scales with patients, not with clinic floor space or equipment.

The GLP-1 Opportunity and Regulatory Risk

The weight loss category was Hims & Hers’ most significant revenue growth catalyst in FY2023–2024. When the FDA placed semaglutide (the active ingredient in Novo Nordisk’s Ozempic and Wegovy) on the drug shortage list, 503A and 503B compounding pharmacies were legally permitted to compound versions of the drug. Hims & Hers moved quickly:

• Launched compounded semaglutide at $199–$299/month vs. branded Wegovy at $1,300+/month
• Built out GLP-1 prescriber capacity within its medical group network
• Acquired compounding pharmacy scale to fulfill surging demand
• Grew weight loss subscribers from near zero in early 2023 to a significant portion of the subscriber base by FY2024

The FDA declared the semaglutide shortage resolved in February 2025. Under FDA rules, this means compounding pharmacies can no longer compound copies of brand-name GLP-1 drugs. Hims & Hers’ legal strategy in response: its compounded formulations include added ingredients (B12, cyanocobalamin, or other compounds), making them “personalized” medications legally distinct from branded semaglutide. The legal and regulatory standing of this approach remains contested — Novo Nordisk and Eli Lilly have lobbied aggressively for FDA enforcement.

This is the pivotal strategic question for Hims & Hers: whether its personalized compounding approach survives regulatory scrutiny, or whether the weight loss category headwinds force a pivot to other growth vectors.

Non-GLP-1 Business: The Durable Core

Even setting aside GLP-1, Hims & Hers has built a durable DTC healthcare platform:

Hair loss remains the company’s oldest and most established category. Finasteride (generic Propecia) and minoxidil (generic Rogaine) are inexpensive generics that Hims & Hers packages into personalized topical formulations through compounding. Male pattern baldness affects ~50% of men by age 50 — a massive, chronic addressable market with near-zero cure probability (treatment must continue indefinitely to maintain results).

Erectile dysfunction generates high-value prescriptions (sildenafil, tadalafil) at low cost. Generic ED medications are cheap to produce; the value Hims delivers is discretion, convenience, and ongoing access without an embarrassing in-person conversation. The compounded chewable sildenafil (“Hims Gummies”) has been a marketing success.

Mental health (SSRIs, anti-anxiety) is a growing category with significant addressable demand — 21% of U.S. adults experience mental illness annually, but access to psychiatric care is severely constrained. Hims & Hers can prescribe and deliver SSRIs like sertraline through its platform at prices comparable to or below insurance copays.

Skincare (tretinoin, anti-aging, hyperpigmentation) targets the intersection of dermatology and cosmetics — a high-ARPU category where compounded personalized formulations offer differentiation against over-the-counter alternatives.

Hims & Hers (HIMS) Competitors

Novo Nordisk and Eli Lilly are the most important competitive forces in the GLP-1 segment. They manufacture the branded GLP-1 drugs (Ozempic, Wegovy, Mounjaro, Zepbound) that Hims & Hers’ compounded formulations are modeled after. Their lobby pressure on the FDA is the primary regulatory risk for Hims’ weight loss business. They also both operate or are developing patient access programs that could compete directly with Hims’ DTC model. See the Eli Lilly vs. Novo Nordisk comparison for context on the GLP-1 market.

Ro (Roman/Rory) is the closest private-company competitor — a DTC telehealth platform covering ED, hair loss, fertility, and weight loss with a near-identical business model. Ro is private, backed by significant VC funding, and has been aggressively expanding into GLP-1.

Amazon Clinic is a nascent but potentially large threat. Amazon launched a telehealth and prescription delivery service that competes with Hims’ convenience proposition, with the added trust, logistics, and Prime membership integration that no other competitor can match. If Amazon aggressively expands Amazon Clinic across the conditions Hims addresses, it could be a material competitive threat.

CVS Health (MinuteClinic) and retail pharmacy-based telehealth are the traditional healthcare establishment’s response to the DTC telehealth wave. CVS competes for the same patient who might otherwise use Hims — offering in-person convenience alongside pharmacy fulfillment. CVS’s strength is the existing pharmacy relationship and insurance integration; Hims’ advantage is price, discretion, and digital convenience.

UnitedHealth Group / Optum owns a large physician group and telehealth platform through Optum. Enterprise telehealth at this scale doesn’t directly compete with Hims’ consumer brand, but it does address the same underlying access problem in mental health and primary care.

Pfizer and Merck make branded versions of drugs (including Viagra, which Pfizer originated) that Hims sells in generic/compounded form. The brand vs. generic dynamic is favorable to Hims — generic pricing has driven significant volume.

Noom and WeightWatchers (WW) compete in the weight management category but with behavioral/coaching approaches rather than medication. As GLP-1 drugs become more normalized, these companies are also pivoting to offer medication-assisted weight loss — increasing competitive overlap.

Revenue Breakdown

All values in millions USD.

The FY2024 revenue story: Hims & Hers more than doubled its FY2022 revenue ($527M) in just two years. The online segment grew +62.3% — sustained by GLP-1 adoption, ongoing strength in hair loss and ED, and mental health category expansion. Wholesale grew +271% from a small base, reflecting growing retail distribution through drugstores and mass-market retailers.

The online segment itself breaks down informally (Hims doesn’t fully disaggregate by condition):

Category estimates are based on publicly disclosed subscriber trends and investor presentations; Hims does not formally segment revenue by condition.

Hims & Hers Business Segment Deep-Dive

Weight Loss / GLP-1 (Largest Growth Driver)

The GLP-1 entry transformed Hims & Hers’ growth trajectory. Compounded semaglutide at $199–$299/month brought in subscribers who would never have paid $1,300+ for branded Wegovy — unlocking a massive price-sensitive demand pool. The compounding model allowed Hims to offer:

• Personalized dosing: Custom titration schedules based on patient response, not the standard fixed-dose packaged drug
• Combined formulations: Semaglutide combined with B12, NAD, or other compounds for personalized protocols
• Monthly injectable kits: Including supplies and detailed administration instructions

The legal risk crystallized in February 2025 when the FDA declared the semaglutide shortage resolved. Hims’ response has been to defend its “personalized compounding” argument — that its formulations are clinically distinct from branded drugs, not mere copies — and to diversify toward tirzepatide (the active ingredient in Eli Lilly’s Mounjaro/Zepbound), for which shortage status may apply separately.

Hair Loss (High-Retention Core)

Hair loss was Hims’ original category and remains a cornerstone of the business. Finasteride ($10–30/month at compounded prices) and minoxidil are the workhorses. The compounding advantage is particularly strong here: Hims can offer topical minoxidil + finasteride combinations, oral minoxidil, and customized concentrations that generic brand equivalents don’t provide in finished form.

Key economics: Hair loss patients who see results within 3–6 months are highly unlikely to stop treatment — pausing finasteride accelerates hair loss. This creates extremely high retention and long LTV. Customer acquisition costs are front-loaded; the gross profit per subscriber compounds over years.

Erectile Dysfunction (High-ARPU Category)

Sildenafil (generic Viagra, $1–2/pill at compounded prices vs. $70+ for branded) and tadalafil are the primary products. Hims’ market innovation: compounded chewable sildenafil (“Hims Gummies”), which is a differentiated format that branded generic manufacturers don’t offer. Compounded chewables are faster-acting and more discreet than standard tablets.

ED is a condition most men won’t discuss with a primary care doctor — Hims’ digital, discreet model addresses this access barrier directly. The addressable market is large: approximately 30 million American men experience ED to some degree.

Mental Health (Expanding Category)

Hims & Hers offers prescriptions for SSRIs (sertraline, escitalopram, bupropion), anti-anxiety medications, and access to online therapy. This category has significant tailwinds — mental health awareness is increasing, stigma is decreasing, and traditional psychiatric access is severely constrained (median wait for a psychiatrist appointment: 25 days). Hims’ async model provides faster access.

The risk: mental health prescribing involves more clinical complexity and liability than hair loss or ED. The requirement for ongoing monitoring and the potential for patient harm if inappropriately prescribed creates a higher-quality-bar clinical model. Hims’ prescribing practices in mental health have been the subject of scrutiny.

Hims & Hers (HIMS) Income Statement

All values in millions USD. Financial data sourced from Hims & Hers SEC Filings.

The income statement reveals powerful operating leverage: revenue grew +65.3% while operating expenses grew only +52.4%, allowing $168M of operating income from a baseline of essentially breakeven. Gross profit grew even faster (+75.2%) than revenue, driven by improving gross margins (+380 bps) as the in-house compounding mix shifted favorably. The shift from -$22M to +$126M net income in a single year marks the company’s transition from growth-at-all-costs to profitable growth.

Hims & Hers (HIMS) Key Financial Metrics

Key Metric Observations

The gross margin trajectory is the most important signal. At 66.1% in FY2024, up from 62.3% in FY2023, Hims & Hers is proving that scale improves margins — the fixed costs of the compounding pharmacy and provider network are being spread over a rapidly growing subscriber base. If this trajectory continues, 70%+ gross margins are achievable, which would make the unit economics extraordinary for a healthcare company.

Operating margin at 8.5% has a long runway. Marketing and customer acquisition is the primary operating expense — as Hims grows its subscriber base, the cost to acquire new subscribers can be partially offset by upsell revenue from existing subscribers (a hair loss customer becoming a weight loss customer costs zero in incremental CAC). If the subscriber base grows to 3M+ with similar ARPU, operating margins of 15–20% are mathematically plausible.

The GLP-1 risk is an earnings risk, not an existential risk. Even if Hims loses its compounded semaglutide business entirely (a worst-case scenario), the hair loss, ED, mental health, and skincare businesses continue growing and generating strong gross margins. The GLP-1 disruption would be painful (potentially a 20–30% revenue headwind) but not company-ending.

Is Hims & Hers (HIMS) Profitable?

Yes — and 2024 was the first full year of meaningful GAAP profitability.

• Gross margin: 66.1% — among the highest of any consumer healthcare company
• Operating margin: 8.5% ($168M operating income) — positive for the first full year after years of growth investment
• Net income: $126M (6.4% net margin) — vs. a $22M loss in FY2023
• Free cash flow: ~$150–180M — the business is now self-funding growth

The path to sustained, improving profitability requires: (1) maintaining subscriber retention in the core categories (hair, ED, mental health) regardless of GLP-1 outcomes; (2) managing marketing spend efficiency as organic and word-of-mouth acquisition grows; and (3) diversifying the weight loss category to reduce GLP-1 regulatory concentration.

Where Does Hims & Hers Spend its Money?

Cost of Revenue (~$668M, 33.9% of revenue)

Covers: pharmaceutical ingredients (APIs purchased for compounding), compounding labor and pharmacy operations, packaging, shipping, and third-party pharmacy fulfillment costs. The 33.9% COGS ratio is low for a physical products business — reflecting the favorable economics of compounding at scale. GLP-1 medications have higher ingredient costs than hair loss or ED formulations; as the mix shifts, COGS may fluctuate.

Marketing & Customer Acquisition (~$620M, ~31% of revenue)

The largest operating expense — paid digital advertising (Meta, Google, TikTok), TV and podcast campaigns, influencer partnerships, and referral programs. DTC healthcare is an attention-intensive business: patients don’t spontaneously search for “compounded semaglutide” — they respond to advertising that creates awareness and conversion. High marketing intensity is the inherent cost of the DTC model vs. insurance-based distribution.

Operations & Provider Costs (~$280M, ~14% of revenue)

Licensed provider (physician, NP, PA) compensation for conducting consultations, pharmacist costs, customer service, and technology infrastructure. This scales with subscriber volume but has components that benefit from automation — async consultation workflows reduce per-patient provider time significantly.

Research & Development (~$130M, ~7% of revenue)

Product development (new treatment categories, new formulations), technology platform engineering (the hims/hers.com apps and back-end), and clinical research. As Hims expands into new health categories, R&D investment drives pipeline development.

General & Administrative (~$104M, ~5% of revenue)

Executive management, legal and compliance (significant — FDA regulatory, state pharmacy board licensing across 50 states, HIPAA compliance, medical group governance), and corporate infrastructure.

Hims & Hers vs. Comparable Healthcare Companies

Hims & Hers is a distributor and prescriber layered on top of the GLP-1 wave; Novo Nordisk and Eli Lilly are the manufacturers of the branded GLP-1 drugs. Their margins (~80–83% gross) are higher because branded pharmaceutical pricing power is far superior to compounded generics. Hims’ growth rate (+65%) is far higher because it is in an earlier stage of market penetration.

Hims & Hers History and Milestones

Hims & Hers (HIMS): What to Watch

1. GLP-1 Regulatory Resolution: The Defining Business Risk The FDA’s February 2025 declaration that the semaglutide shortage is over is the most important development in Hims & Hers’ history. The company’s argument that its personalized compounded formulations are legally distinct from brand-name Ozempic/Wegovy is being contested by Novo Nordisk, Eli Lilly, and others lobbying the FDA for enforcement. If the FDA rules that Hims’ current formulations violate the shortage-resolution rules, the weight loss category could lose a significant portion of its subscriber base. The timeline of any FDA enforcement action, court decisions on legal challenges to FDA policy, and the pace of subscriber attrition from the weight loss category are the metrics to watch quarterly.

2. Subscriber Count and Retention Across All Categories Hims does not provide detailed subscriber counts by category, but total subscriber growth and revenue-per-subscriber trends are disclosed or derivable. The critical question post-GLP-1 peak: how well does the hair loss, ED, and mental health subscriber base retain? If subscribers who initially joined for weight loss are converting to other Hims treatments (hair, skin, mental health), the platform stickiness thesis is validated. If they churn, the customer acquisition cost was wasted.

3. Gross Margin Trajectory: Compounding Scale vs. GLP-1 Mix Shift The 66.1% gross margin in FY2024 benefited from the GLP-1 compounding economics. As the GLP-1 mix potentially shrinks, and as non-GLP-1 categories (which may have different cost structures) grow, gross margin will shift. Monitoring whether gross margin expands or contracts from 66% is the key signal on unit economics health.

4. Amazon Clinic and Retail Pharmacy Competition Amazon Clinic launched telehealth prescribing in 2023 and has been quietly expanding. With Amazon Pharmacy integration, Prime membership advantages, and enormous existing healthcare data, Amazon could become a formidable DTC telehealth competitor if it chooses to invest aggressively. Any major Amazon Clinic product announcement in the hair loss, ED, or mental health categories would be a material competitive signal for Hims.

5. Tirzepatide Entry: The GLP-1 Diversification Play Tirzepatide (the active ingredient in Eli Lilly’s Mounjaro and Zepbound) is a dual GIP/GLP-1 receptor agonist that may be clinically superior to semaglutide for weight loss. If tirzepatide remains on shortage, Hims can legally compound it. Hims has been expanding its tirzepatide offerings as a diversification from semaglutide. Whether tirzepatide shortage status is maintained and whether Hims’ tirzepatide formulations can replace the lost semaglutide volume are critical 2025–2026 growth questions.

6. Operating Leverage: Marketing Efficiency as the Business Matures Hims & Hers spends approximately 31% of revenue on marketing — a high rate that reflects the DTC customer acquisition imperative. As the subscriber base grows and word-of-mouth and brand recognition improve, the CAC-to-LTV ratio should improve. If revenue scales to $3–4B with marketing holding at 25–28% of revenue, the incremental gross profit drops predominantly to operating income. Operating margin of 15%+ is the target that would validate the investment thesis.

7. New Category Expansion: Primary Care, Dental, Fertility Hims has signaled ambitions to expand beyond its current six categories into primary care, men’s fertility, and potentially dental health. Each new category adds TAM but also requires clinical infrastructure, regulatory compliance in each specialty, and marketing investment to create awareness. The cross-sell potential — using an existing subscriber relationship to introduce a new category — is the capital-efficient way to expand. Track new category launches and the rate at which existing subscribers adopt them.

8. Competition from CVS Health and UnitedHealth CVS Health owns Aetna, MinuteClinic, and one of the largest pharmacy networks in the U.S. UnitedHealth Group owns Optum, which operates telehealth and physician groups. Both companies have the financial resources, patient relationships, and insurance integration to compete with Hims in DTC telehealth if they choose to. Neither has aggressively attacked Hims’ core markets yet — but the threat of a well-resourced incumbent pivot into the discretionary telehealth space is a long-term competitive risk.

Hims & Hers (HIMS) Financial Summary

Hims & Hers Health (HIMS) is a healthcare and pharmaceuticals adjacent company that generated $1.97 billion in total revenue in FY2024 — up +65.3% year-over-year — driven by GLP-1 weight loss subscriptions and sustained growth in hair loss, ED, and mental health categories. Gross margin of 66.1% is exceptional for a physical product business, reflecting the direct-to-consumer model, in-house compounding pharmacy, and low-cost digital consultation delivery.

Operating margin of 8.5% ($168M) and net income of $126M mark FY2024 as the first year of sustained GAAP profitability. Free cash flow of ~$150–180M makes the business self-funding. The operating leverage story — opex growing at 52% vs. revenue at 65% — suggests margins should continue expanding as the subscriber base scales.

The pivotal risk: the FDA’s resolution of the semaglutide drug shortage (February 2025) creates legal uncertainty around the GLP-1 compounding model that drove much of FY2023–2024 growth. The outcome of this regulatory battle — against Novo Nordisk and Eli Lilly lobbying — will define Hims’ growth trajectory through 2026 and beyond.

Related companies include Novo Nordisk, Eli Lilly, Pfizer, Merck, Amazon, CVS Health, UnitedHealth Group, Johnson & Johnson, and Abbvie.

Frequently Asked Questions

How does Hims & Hers make money? Through a direct-to-consumer subscription model. Customers pay for recurring treatment plans (hair loss, ED, weight loss, mental health, skincare) — online consultations followed by monthly medication delivery. FY2024: $1.97B revenue (+65.3%), 97% from online subscriptions.

Is Hims & Hers profitable? Yes. FY2024: $168M operating income (8.5% margin), $126M net income, ~$150–180M free cash flow. First full year of GAAP profitability, after near-breakeven in FY2023.

What is the GLP-1 risk? Hims offered compounded semaglutide (the GLP-1 active ingredient in Ozempic/Wegovy) during an FDA-declared drug shortage. The FDA resolved the shortage in February 2025, making standard compounded copies illegal. Hims pivoted to “personalized” formulations with added ingredients. The legal standing of this approach is contested by Novo Nordisk and Eli Lilly.

What is Hims & Hers’ gross margin? 66.1% in FY2024 — exceptional for a company shipping physical medications. Driven by the DTC model (no retail intermediaries), in-house compounding pharmacy (manufactures at API cost), and low-cost digital consultations.

What conditions does Hims treat? Hair loss (finasteride, minoxidil), erectile dysfunction (sildenafil, tadalafil), weight loss (compounded GLP-1, tirzepatide), mental health (SSRIs, therapy), skincare (tretinoin, hyperpigmentation), and primary care.

Who are Hims & Hers’ main competitors? Ro (Roman/Rory, private) in DTC telehealth; Novo Nordisk and Eli Lilly in GLP-1 brands; Amazon Clinic in DTC healthcare; CVS Health in retail pharmacy telehealth; Noom in behavioral weight loss.

How does the compounding pharmacy model work? Hims operates its own PCAB-accredited compounding pharmacy, which legally creates customized medications tailored to individual patient prescriptions. This allows Hims to offer personalized formulations (e.g., semaglutide + B12, topical finasteride + minoxidil combined) at prices far below branded equivalents, at costs reflecting API ingredients + compounding labor rather than brand-name drug prices.

What is Hims & Hers’ revenue growth rate? +65.3% in FY2024 ($1.97B vs. $1.19B in FY2023). One of the fastest growth rates among public healthcare companies. Growth was primarily GLP-1-driven, with strong contributions from hair loss, ED, and mental health.